Microsoft word - 2013年度薬理業績_英語.docx

2014 / In Press

1. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, Rajji TK, Mamo DC. Therapeutic window for striatal dopamine D2/3 receptor occupancy in older patients with schizophrenia: a pilot PET study. Am J Geriatr 2. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharm. (in press) Both authors have contributed equally. 3. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, Mimura M. Incidence of deep vein thrombosis in restrained psychiatric patients. 4. Uchida H, Suzuki T. Dose and dosing frequentry of long-acting injectable antypsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. (in press) 5. Miller JM, Schneck N, Siegle GJ, Chen Y, Ogden RT, Kikuchi T, Oquendo MA, Mann JJ, Parsey RV. fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study. Psychiatry Research: Neuroimaging. (in press) 6. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once vs. twice daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. J Clin Psychiatry. (in press) 7. Tsuboi T, Uchida H, Suzuki T, Mimura M. Effectiveness of Saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexcual dysfunction in male patients with schizophrenia: A description of two cases. 8. Tada M, Uchida H, Suzuki T, Abe T, Pollock BG, Mimura M. Baseline difference between patients’ and clinicians’ rated illness severity scores and subsequent outcomes in major depressive disorder: analysis of the STAR*D 9. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A.Ventral Striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. Biol Psychiatry. (in press) 10. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-Acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 40:192-213, 2014. 11. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull (in press) 1. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res. 2013; 2. Sakurai H, Bies RR, Stroup SE, Keefe RSE, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. 3. Tanaka S, Nagase T, Suzuki T, Nomura K, Takeuchi H, Nakajima S, Uchida H, Yagi G, Watanabe K, Mimura M. Factor structure of the targeted inventory on problems in schizophrenia. Clin Psychopharmacology and Neuroscience. 4. Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock BG, Mulsant B, Deluca V, Ismail Z, Mamo D. Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology. 2013; 228(1): 43-51. 5. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll C, Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophr Res. 2013; 147(2-3): 383-6. 6. Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D2 Receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin 7. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatric Res. 2013; 209(3):406-11. 8. Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y. Reintroduction of clozapine after perforation of the large intestine - A case report and review of the literature. Ann Pharmacother. 2013;47(7-8): e31. 9. Yoshida K, Suzuki T, Uchida H, Mimura M. Absence of evidence that p.r.n. regimen confers benefit: A review of the studies. Int Clinical 10. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Association between antidepressant side effects and functional impairment in patients with major depressive disorders. Psychiatry Res. 2013; 210(1):127-33. 11. Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy and in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:178-82. 12. Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H. 10-year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Int Clin Psychopharm. 2013; 28(5): 13. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013; 39(5): 14. Sakurai H, Uchida H, Abe T, Nakajima S, Suzuki T, Pollock BG, Sato Y, Mimura M. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord. 2013; 151(2): 506-13. 15. Ikai S, Uchida H, Suzuki T, Tsunoda K, Mimura M, Fujii Y. Effects of yoga therapy on postural stability in schizophrenia: a single-blind randomized controlled trial. J Psychiatr Res. 2013; 47(11): 1744-50. 16. Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishi M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Ookubo Y, Kato M. An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatr Dis Treat. 2013; 9: 1553-1564. 17. Koizumi T, Uchida H, Suzuki T, Sakurai H, Tsunoda K, Nishimoto M, Ishigaki T, Goto M, Mimura M. Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. Gen Hosp Psychiatry. 2013; 35(6): 18. Mizushima J, Sakurai H, Mizuno Y, Shinfuku M, Tani H, Yoshida K, Ozawa C, Serizawa A, Koide S, Kodashiro N, Minamisawa A, Mutsumoto E, Nagai N, Noda S, Tachino G, Takahashi T, Takeuchi H, Kikuchi T, Uchida H, Watanabe K, Kocha H, Mimura M. Melancholic and reactive depression: a reappraisal of old categories. BMC Psychiatry. 2013; 13: 311. 19. Takeuchi T, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophr Res. 20. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol 21. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 22. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013; 66(8 Suppl):S37-41. 23. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3):216-26. 24. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies. J Clin Psychiatry. 2013; 25. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2013; 23(10):665-75. 26. Kubota K, Okazaki M, Dobashi A, Yamamoto M, Hashiguchi M, Horie A, Inagaki A, Kikuchi T, Mochizuki M. Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan. Pharmacoepidemiol Drug Saf. 2013; 27. Takeuchi H, Remington G. A Systematic Review of Reported Cases Involving Psychotic Symptoms Worsened by Aripiprazole in Schizophrenia or Schizoaffective Disorder. Psychopharmacology. 2013; 228(2): 175-85, 2013. 28. Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, Graff-Guerrero A.The potential role of dopamine D₃ receptor neurotransmission in cognition.Eur Neuropsychopharmacol. 2013; Kane JM, Kishimoto T, Correll CU. The Comparative Effectiveness of Long-Acting Injectable vs. Oral Antipsychotic Medications in the Prevention of Relapse: A Case Study in CER in Psychiatry J Clin Epidemiol. 2013; 66(8 Suzuki T Uchida H, Watanabe K, Mimura M. In Michael S. Ritsner, eds. Polypharmacy in Psychiatry Practice. Volume 2. Use of Polypharmacy in the “Real World”. Part Ⅰ Antipsychotic Polypharmacy. Chapter 6. Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice? Sawada N, Uchida H, Watanabe K, Kikuchi T, Suzuki T, Kashima H, Mimura M. How accurate are physicians in eliciting the truth from their patients?: a large-scale internet survey from patients’ perspectives. J Clin Zahinoor I, Wessels A, Uchida H, Ng W, Mamo D, Rajji T, Pollock B, Mulsant B, Bies R. Age effects on clozapine clearance: age impacts clozapine exposure in inpatients and outpatients with schizophrenia. Am J Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012; 134(2-3): 219-25. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, Mimura M, Mamo DC. Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res. Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. Prog Neuropsychopharmacol Biol Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. J Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo DC, *Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: Implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry. 2012; 73: Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic polypharmacy in schizophrenia begins – a longitudinal perspective. Kikuchi T, Miller JM, Schneck N, Oquendo MA, Mann JJ, Parsey RV, Keilp JG. Neural responses to incongruency in a blocked-trial Stroop fMRI task in major depressive disorder. J Affect Disord. 2012; 143:241-7. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Coping strategies for antidepressant side effects: An Internet survey. J Affect Disord. 2012; Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012; Nio S, Suzuki T, Uchida H, Watanabe K, Mimura M. Deficit status in bipolar disorder: investigation on prevalence rate and description of seven cases. J Affect Disord. 2012;143:248-52. Kato Y, Uchida H, Mimura M. Mental health and psychosocial support after the Great East Japan Earthquake. Keio J Med. 2012; 61:15-22. Suzuki T. Discontinuing donepezil or starting memantine for Alzheimer’s disease. N Engl J Med. 2012; 366:2227-8. Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic polypharmacy in schizophrenia begins – a longitudinal perspective. Tani H, Uchida H, Suzuki T, Shibuya Y, Shimanuki H, Watanabe K, Den R, Nishimoto M, Hirano J, Takeuchi H, Nio S, Nakajima S, Kitahata R, Tsuboi T, Tsunoda K, Kikuchi T, Mimura M. Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. BMC Oral Health. 2012; 12:32. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011; 31(4): 497-502. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2011; 37(4): 788-99. Uchida H, Chow TW, Mamo DC, Kapur S, Mulsant BH, Houle S, Pollock BG, Graff-Guerrero A. Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections. Int J Geriatr Psychiatry. Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S. The evolution of antipsychotic switch and polypharmacy in natural practice–a longitudinal perspective. Schizophr Res. 2011; 130(1-3): 40-6. Tsuboi T, Suzuki T, Uchida H. A tipping point in drug dosing in late-life schizophrenia. Curr Psychiatry Rep. 2011; 13(3): 225-33. Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H, Watanabe K, Kashima H. How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. Suzuki T, Uchida H, Watanabe K, Kashima H. Factors associated with response to clozapine in schizophrenia: A review. Psychipharmacol Bull. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 2011; 28(12): 961-80. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011; 133(1-3): 54-62. Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry. 2011; 199(4): 275-80. Suzuki T. Which rating scales are regarded as ‘the standard’ in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull. 2011; 44(1): Suzuki T. Maternal depression and child development after prenatal DHA supplementation. JAMA. 2011; 305(4): 359-60; author reply 60-1. Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective. Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, Kashima H. Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2011; 65(3): 299. Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Minamisawa A, Suzuki T, Watanabe K, Imasaka Y, Kimura Y, Takeuchi H, Nakajima S, Kashima H, Uchida H. Patient’s trust in their psychiatrist: a cross-sectional survey. Eur Arch Psychiatry Clin Neurosci. 2011; 261(8): Koreki A, Tsunoda K, Suzuki T, Hirano J, Watanabe K, Kashima H, Uchida H. Clinical and demographic characteristics associated with postural instability in patients with schizophrenia. J Clin Psychopharmacol. 2011; Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H. Patients’ attitudes toward side effects of antidepressants: an Internet survey. Eur Arch Psychiatry Clin Neurosci. 2011; 261(2): 103-9. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Kashima H. Subjective recognition of adverse events with antidepressant in people with depression: a prospective study. J Affect Disord. 2011; 135(1-3): 347-53. Ishida T, Uchida H, Suzuki T, Nakajima S, Watanabe K, Kashima H. Plasma substance P level in patients with schizophrenia: a cross-sectional study. Psychiatry Clin Neurosci. 2011; 65(5): 526-8. Hori K, Konishi K, Watanabe K, Uchida H, Tsuboi T, Moriyasu M, Tominaga I, Hachisu M. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer’s disease. Neuropsychobiology. 2011; 63(3): Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci. 2011; 65(7): 676-8. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011; 131(1-3): 58-62. 74. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011; 33(12): B16-39. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011; 13(2): 155-72. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010; 24(1): Uchida H, Suzuki T, Takeuchi H, Mamo DC. Analysis of antipsychotic dose reduction. Am J Psychiatry. 2010; 167(8): 994; author reply -5. Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H. Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry. 2010; Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci. Suzuki T, Uchida H, Nakajima S. Depression severity and effect of antidepressant medications. JAMA. 2010; 303(16): 1597-8; author reply 9. Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G, Watanabe K, Kashima H. Magnitude of rater differences in assessment scales for schizophrenia. J Clin Psychopharmacol. 2010; 30(5): 607-11. Sproule BA, Lake J, Mamo DC, Uchida H, Mulsant BH. Are antipsychotic prescribing patterns different in older and younger adults?: a survey of 1357 psychiatric inpatients in Toronto. Can J Psychiatry. 2010; 55(4): 248-54. Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, Pollock BG, Mulsant BH. Clozapine and global cognition in schizophrenia. J Clin Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(2): Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC. Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep. 2010; 12(1): 28-33. Konishi K, Hori K, Uchida H, Watanabe K, Tominaga I, Kimura M, Hosoyamada M, Shibasaki T, Kataoka A, Hachisu M. Adverse effects of anticholinergic activity on cognitive functions in Alzheimer’s disease. Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evid Based Baharnoori M, Bartholomeusz C, Boucher AA, Buchy L, Chaddock C, Chiliza B, Focking M, Fornito A, Gallego JA, Hori H, Huf G, Jabbar GA, Kang SH, El Kissi Y, Merchan-Naranjo J, Modinos G, Abdel-Fadeel NA, Neubeck AK, Ng HP, Novak G, Owolabi OO, Prata DP, Rao NP, Riecansky I, Smith DC, Souza RP, Thienel R, Trotman HD, Uchida H, Woodberry KA, O’Shea A, DeLisi LE. The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions. 89. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 90. Uchida H, Suzuki T, Watanabe K, Kashima H. Should adjunctive antipsychotic treatment be continued in remitted patients with depression? Psychiatry Clin Neurosci. 2009; 63(1): 126. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H, Kikuchi T, Nakajima S, Nomura K, Tomita M, Watanabe K, Kashima H. Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci. 2009; 63(2): 244-6. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009; 23(4): 477-81. Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, Menon M, Mamo DC. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009; Uchida H, Pollock BG, Bies RR, Mamo DC. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009; 86(4): 360-2. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(6): Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009; 17(3): 98. Uchida H, Graff-Guerrero A, Mulsant BH, Pollock BG, Mamo DC. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. Schizophr Res. 2009; 109(1-3): 130-3. Tanaka H, Ma J, Tanaka KF, Takao K, Komada M, Tanda K, Suzuki A, Ishibashi T, Baba H, Isa T, Shigemoto R, Ono K, Miyakawa T, Ikenaka K. Mice with altered myelin proteolipid protein gene expression display cognitive deficits accompanied by abnormal neuron-glia interactions and decreased conduction velocities. J Neurosci. 2009; 29(26): 8363-71. 100. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J Clin Psychopharmacol. 2009; 29(4): 101. Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, Yagi G, Watanabe K, Kashima H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009; 24(8): 628-38. 102. Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, Kashima H. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009; 9: 38. 103. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry. 104. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 105. Nakajima S, Uchida H, Suzuki T, Watanabe K, Kashima H. Selective serotonin reuptake inhibitor-induced spermatorrhea in 2 patients. J Clin 106. akajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2009. 107. Nakajima S, Suzuki T, Uchida H, Watanabe K, Kashima H. Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(1): 108. Nakajima S, Ishida T, Akaishi R, Takahata K, Kitahata R, Uchida H, Suzuki T, Takeuchi H, Nomura K, Nakagawa A, Watanabe K, Kashima H. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. J ECT. 2009; 25(3): 178-81. 109. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (3): CD006529. 110. Nakagawa A, Grunebaum MF, Oquendo MA, Burke AK, Kashima H, Mann JJ. Clinical correlates of planned, more lethal suicide attempts in major depressive disorder. J Affect Disord. 2009; 112(1-3): 237-42. 111. Deltheil T, Tanaka K, Reperant C, Hen R, David DJ, Gardier AM. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int J Neuropsychopharmacol. 2009: 1-11. 112. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (2): CD006532. 113. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (2): CD006117. 114. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 115. Chow TW, Mamo DC, Uchida H, Graff-Guerrero A, Houle S, Smith GS, Pollock BG, Mulsant BH. Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults. BMC Med Imaging. 2009; 9: 12. 116. Barbui C, Cipriani A, Furukawa TA, Salanti G, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, Geddes JR. Making the best use of available evidence: the case of new generation antidepressants: a response to: are all antidepressants equal? Evid Based Ment Health. 2009; 12(4): 117. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the 118. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry. 2008; 69(9): 1404-15. 119. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008; 16(7): 584-93. 120. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann SW, Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008; 69(8): 1281-6. 121. Toda T, Hayakawa I, Matsubayashi Y, Tanaka K, Ikenaka K, Lu QR, Kawasaki H. Termination of lesion-induced plasticity in the mouse barrel cortex in the absence of oligodendrocytes. Mol Cell Neurosci. 2008; 39(1): 122. Tatsumi K, Takebayashi H, Manabe T, Tanaka KF, Makinodan M, Yamauchi T, Makinodan E, Matsuyoshi H, Okuda H, Ikenaka K, Wanaka A. Genetic fate mapping of Olig2 progenitors in the injured adult cerebral cortex reveals preferential differentiation into astrocytes. J Neurosci Res. 2008; 123. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki H, Watanabe K, Kashima H. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008; 28(5): 540-3. 124. Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum 125. Suzuki T, Uchida H, Watanabe K, Kashima H. A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication. Psychopharmacol Bull. 2008; 41(1): 164-70. 126. Suzuki T, Uchida H, Watanabe K, Kashima H. Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacol 127. Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi G, Watanabe K, Kashima H. Novel rating scales for schizophrenia – Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). 128. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. CNS Drugs. 2008; 22(7): 587-602. 129. Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK, Brent DA, Mann JJ, Oquendo MA. Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality? Bipolar Disord. 2008; 10(4): 130. Masuda M, Tanaka KF, Kanzaki S, Wakabayashi K, Oishi N, Suzuki T, Ikenaka K, Ogawa K. GFAP aggregates in the cochlear nerve increase the noise vulnerability of sensory cells in the organ of Corti in the murine model of Alexander disease. Neurosci Res. 2008; 62(1): 15-24. 131. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008; 69(1): 81-6. K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008; 69(3): 385-91. 133. Fujisawa D, Hashimoto N, Masamune-Koizumi Y, Otsuka K, Tateno M, Okugawa G, Nakagawa A, Sato R, Kikuchi T, Tonai E, Yoshida K, Mori T, Takahashi H, Sato S, Igimi H, Waseda Y, Ueno T, Morokuma I, Takahashi K, Sartorius N. Pathway to psychiatric care in Japan: A multicenter observational study. Int J Ment Health Syst. 2008; 2(1): 14. 134. Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Reperant C, Guilloux JP, Coudore F, Hen R, Gardier AM. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology. 2008; 55(6): 135. Cipriani A, Furukawa TA, Geddes JR, Malvini L, Signoretti A, McGuire H, Churchill R, Nakagawa A, Barbui C. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry. 2008; 69(11): 136. Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T, Itohara S, Kato H, Ikenaka K. Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. Glia. 2007; 137. Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?–A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl). 2007; 195(2): 285-95. 138. Suzuki T, Uchida H, Watanabe K, Kashima H. Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1141-2. vSuzuki T, Uchida H, Watanabe K, Kashima H. Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. J Clin Pharm Ther. 2007; 32(5): 525-7. 139. Nakajima S, Uchida H, Suzuki T, Tomita M, Tsunoda K, Kitta M, Takeuchi H, Nomura K, Watanabe K, Kashima H. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. J Clin 140. Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry. 2007; 68(6): 908-16. 141. Ma J, Tanaka KF, Yamada G, Ikenaka K. Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem 142. Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y, Watanabe K, Imasaka Y, Kashima H. Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect. J Clin Psychopharmacol. 2006; 26(1): 50-5. 143. Uchida H, Suzuki T, Watanabe K, Kashima H. Antipsychotics-induced hypersensitivity of visual perception. Eur Psychiatry. 2006; 21(5): 343-4. 144. Tanaka KF, Ochi N, Hayashi T, Ikeda E, Ikenaka K. Fluoro-Jade: new fluorescent marker of Rosenthal fibers. Neurosci Lett. 2006; 407(2): 127-30. 145. Nakagawa A, Sato T, Endo Y, Watanabe K, Kashima H, Grunebaum MF. Prospective study of falls in long-term inpatients with chronic psychotic disorders. Schizophr Res. 2006; 88(1-3): 283-5. 146. Ma J, Matsumoto M, Tanaka KF, Takebayashi H, Ikenaka K. An animal model for late onset chronic demyelination disease caused by failed terminal differentiation of oligodendrocytes. Neuron Glia Biol. 2006; 2(2): 81-91. 147. Uchida H, Watanabe K, Suzuki T, Goto A, Kashima H. Two case reports of successful prevention of overdosing in borderline patients. Psychiatry. 148. Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol. 2005; 149. Suzuki T, Uchida H, Takeuchi H, Nomura K, Tanabe A, Watanabe K, Yagi G, Kashima H. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl). 2005; 181(3): 566-75. 150. Kishimoto T, Watanabe K, Takeuchi H, Kikuchi T, Nakajima S, Shimada N, Yagi G, Kashima H. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res. 2005; 77(1): 113-5. 151. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(2): 361-9. 152. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004; 7(2): 133-42. 153. Uchida H, Suzuki T, Watanabe K, Yagi G, Kashima H. Antipsychotic-induced paroxysmal perceptual alteration. Am J Psychiatry. 154. Uchida H, Suzuki T, Tanaka KF, Watanabe K, Yagi G, Kashima H. Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents. J Clin Psychopharmacol. 2003; 23(5): 496-9. 155. Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol. 2003; 18(6): 323-9. 156. Tanaka KF, Kashima H, Suzuki H, Ono K, Sawada M. Existence of functional beta1- and beta2-adrenergic receptors on microglia. J Neurosci 157. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res. 2000; 96(1): 75-80. 158. Fujino T, Hasegawa M, Shibata S, Kishimoto T, Imai S, Takano T. PCCX1, a novel DNA-binding protein with PHD finger and CXXC domain, is regulated by proteolysis. Biochem Biophys Res Commun. 2000; 271(2): 305-10.

Source: http://psy.keiomed.jp/pdf/yakuri_en.pdf